doxorubicin - CISMeF

Preferred Label : doxorubicin;

MeSH definition : Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.;

CISMeF synonym : pharmacia brand of doxorubicin hydrochloride; 25316-40-9 (Doxorubicin hydrochloride); DOX SL; Bristol-Myers squibb brand of doxorubicin hydrochloride; baxter brand of doxorubicin hydrochloride; bedford brand of doxorubicin hydrochloride; cell pharm brand of doxorubicin hydrochloride; columbia brand of doxorubicin hydrochloride; elan brand of doxorubicin hydrochloride; ferrer brand of doxorubicin hydrochloride; hexal brand of doxorubicin hydrochloride; kenfarma brand of doxorubicin hydrochloride; lemery brand of doxorubicin hydrochloride; medac brand of doxorubicin hydrochloride; neocorp brand of doxorubicin hydrochloride; onkoworks brand of doxorubicin hydrochloride; pfizer brand of doxorubicin hydrochloride; prasfarma brand of doxorubicin hydrochloride; ribosepharm brand of doxorubicin hydrochloride; tedec meiji brand of doxorubicin hydrochloride;

MeSH hyponym : adrimedac; doxorubicin NC; myocet; doxorubicina ferrer farm; rubex; adriblastin; doxorubicina tedec; onkodox; doxorubicina funk; doxorubicin hydrochloride; doxotec; doxorubicine baxter; doxolem; adriamycin; DOXO-cell; doxorubicin hexal; ribodoxo; farmiblastina; Adriblastine; Adriblastina; Adriablastine; Adriablastin; DOXO cell; Urokit Doxo-cell; Urokit Doxo cell; Hydrochloride, Doxorubicin;

MeSH CAS label : 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;

MeSH Related Number : doxorubicin hydrochloride; 23214-92-8 (Doxorubicin); 25316-40-9 (HCl); 82F2G7BL4E;

Registry Number MeSH : 23214-92-8;

Related CAS MeSH : 82F2G7BL4E (Doxorubicin hydrochloride);

MeSH annotation : Xref CAELYX or LIPOSOMAL DOXORUBICIN coord with LIPOSOMES (NIM);

Wikipedia link : https://en.wikipedia.org/wiki/Doxorubicin;

Codes EINECS : 245-495-6;

Is substance : O;

UNII : 80168379AG;

InChIKey : AOJJSUZBOXZQNB-TZSSRYMLSA-N;

Details

Origin ID

D004317;

UMLS CUI

C0013089;

ATC code(s)
- doxorubicin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Doxorubicin Hydrochloride [NCIt concept]
- Doxorubicin hydrochloride (substance) [SNOMED CT concept]
- Nanoparticle-encapsulated Doxorubicin Hydrochloride [NCIt concept]
- doxorubicin hydrochloride [SNOMED Notion]
CISMeF manual mappings
- Doxorubicin poisoning (disorder) [SNOMED CT concept]
- doxorubicin [Substance BNPC]
Currated CISMeF NLP mapping
- DOXOrubicin [LOINC component]
- Doxorubicin [ICD-11 Extension code]
- Doxorubicin [ICHI extension code]
- Doxorubicin [SMS substance]
- Doxorubicin [NCIt concept]
- Doxorubicin (substance) [SNOMED CT concept]
- doxorubicin [SNOMED Notion]
Indexing information
- DrrA protein, streptomyces peucetius [MeSH Supplementary Concept]
Pharmacological action(s)
- antibiotics, antineoplastic [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
- topoisomerase II inhibitors [MeSH Descriptor]
Record concept(s)
- DOXO-cell [MeSH concept]
- adriamycin [MeSH concept]
- adriblastin [MeSH concept]
- adrimedac [MeSH concept]
- doxolem [MeSH concept]
- doxorubicin [MeSH concept]
- doxorubicin NC [MeSH concept]
- doxorubicin hexal [MeSH concept]
- doxorubicin hydrochloride [MeSH concept]
- doxorubicina ferrer farm [MeSH concept]
- doxorubicina funk [MeSH concept]
- doxorubicina tedec [MeSH concept]
- doxorubicine baxter [MeSH concept]
- doxotec [MeSH concept]
- farmiblastina [MeSH concept]
- myocet [MeSH concept]
- onkodox [MeSH concept]
- ribodoxo [MeSH concept]
- rubex [MeSH concept]
Related MeSH Supplementary Concept(s)
- (COMPADRI)-III protocol [MeSH Supplementary Concept]
- 10-hydroxydesacetyladriamycin [MeSH Supplementary Concept]
- 11-deoxyadriamycin [MeSH Supplementary Concept]
- 13-hydroxydoxorubicin [MeSH Supplementary Concept]
- 14-((N-tetradecylamido)succinyl)doxorubicin [MeSH Supplementary Concept]
- 14-O-acetyldoxorubicin [MeSH Supplementary Concept]
- 14-O-palmitoylhydroxyrubicin [MeSH Supplementary Concept]
- 2,6-diaminopurine aglycone [MeSH Supplementary Concept]
- 3'-acetoxy-4'-O-acetyldoxorubicin [MeSH Supplementary Concept]
- 3'-deamino-3'',4'-anhydro-(2''-methoxy-3''-oxy-4''-morpholinyl)doxorubicin [MeSH Supplementary Concept]
- 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin [MeSH Supplementary Concept]
- 3'-desamino-3'-dimethylformamidinedoxorubicin [MeSH Supplementary Concept]
- 3'-hydroxyesorubicin [MeSH Supplementary Concept]
- 4'-O-methyldoxorubicin [MeSH Supplementary Concept]
- 4'-amino-3'-hydroxydoxorubicin [MeSH Supplementary Concept]
- 4'-deoxy-4'-iododoxorubicin [MeSH Supplementary Concept]
- 4'-deoxydoxorubicinol [MeSH Supplementary Concept]
- 4'-deoxydoxorubicinol 7-deoxyaglycone [MeSH Supplementary Concept]
- 4'-iodo-4'-deoxydoxorubicinol [MeSH Supplementary Concept]
- 4-O-demethyl-11-deoxydoxorubicin [MeSH Supplementary Concept]
- 4-demethoxy-11-deoxyadriamycin [MeSH Supplementary Concept]
- 4-demethoxy-3'-deamino-3'-hydroxydoxorubicin [MeSH Supplementary Concept]
- 4-demethoxy-4'-O-methyldoxorubicin [MeSH Supplementary Concept]
- 4-demethoxy-7-O-(2,6-dideoxy-2-fluorotalopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 4-demethoxydoxorubicin [MeSH Supplementary Concept]
- 4-demethoxydoxorubicinone [MeSH Supplementary Concept]
- 4-demethyl-6-O-methyldoxorubicin [MeSH Supplementary Concept]
- 4-demethyl-6-deoxydoxorubicin [MeSH Supplementary Concept]
- 5-imino-13-deoxydoxorubicin [MeSH Supplementary Concept]
- 5-iminodoxorubicin [MeSH Supplementary Concept]
- 7(O)-(3-amino-2,3,6-trideoxy-2-fluorotalopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7(O)-(6-deoxy-2-O-methyltalopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7,8-dehydro-9,10-desacetyldoxorubicinone [MeSH Supplementary Concept]
- 7-O-(2,3,5-trideoxy-3-C-formylpentafuranosyl)adriamycinone [MeSH Supplementary Concept]
- 7-O-(2,6-Dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluoro--5-C-(trifluoromethyl)talopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluoro-4-O-methyltalopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluorotalopyranose)adriamycinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluro-alpha-talopyranosyl)adriamycinol [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-6,6,6-trifluoro-alpha-L-lyxo-hexopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7-O-(3-amino-2,3,6-trideoxy--6,6,6-trifluoro-lyxo-hexopyranosyl)adriamycinone [MeSH Supplementary Concept]
- 7-O-ribofuranosyladriamycinone [MeSH Supplementary Concept]
- 7-aminocephalosporin doxorubicin-monomethoxypoly(ethylene glycol)propionic acid N-hydroxysuccinimide ester [MeSH Supplementary Concept]
- 7-aminocephalosporin doxorubicin-poly(ethylene glycol)propionic acid N-hydroxysuccinimide ester [MeSH Supplementary Concept]
- 7-deoxy-13-dihydroadriamycinone [MeSH Supplementary Concept]
- 9,10-anhydroadriamycin [MeSH Supplementary Concept]
- 9-deoxydoxorubicin [MeSH Supplementary Concept]
- A-DP1doxorubicin albumin conjugate [MeSH Supplementary Concept]
- A-DP2 doxorubicin albumin conjugate [MeSH Supplementary Concept]
- A-VBM-FH6 protocol [MeSH Supplementary Concept]
- AA1-3 protocol [MeSH Supplementary Concept]
- AAABC protocol [MeSH Supplementary Concept]
- AAAP protocol [MeSH Supplementary Concept]
- ABC protocol [MeSH Supplementary Concept]
- ABCM protocol [MeSH Supplementary Concept]
- ABDIC protocol [MeSH Supplementary Concept]
- ABEP protocol 2 [MeSH Supplementary Concept]
- ABOD protocol [MeSH Supplementary Concept]
- ABP protocol 1 [MeSH Supplementary Concept]
- ABP protocol 2 [MeSH Supplementary Concept]
- ABV-ADV protocol [MeSH Supplementary Concept]
- ABVD protocol [MeSH Supplementary Concept]
- ABVDP protocol [MeSH Supplementary Concept]
- ABVG protocol [MeSH Supplementary Concept]
- AC protocol [MeSH Supplementary Concept]
- ACE protocol 1 [MeSH Supplementary Concept]
- ACF protocol [MeSH Supplementary Concept]
- ACFM protocol [MeSH Supplementary Concept]
- ACFT protocol [MeSH Supplementary Concept]
- ACHM protocol [MeSH Supplementary Concept]
- ACM protocol [MeSH Supplementary Concept]
- ACMFVP protocol [MeSH Supplementary Concept]
- ACMP protocol [MeSH Supplementary Concept]
- ACOB regimen [MeSH Supplementary Concept]
- ACOMLA protocol [MeSH Supplementary Concept]
- ACOP protocol 2 [MeSH Supplementary Concept]
- ACOP-E protocol [MeSH Supplementary Concept]
- ACOPA II protocol [MeSH Supplementary Concept]
- ACP protocol [MeSH Supplementary Concept]
- ACT protocol [MeSH Supplementary Concept]
- ACT regimen [MeSH Supplementary Concept]
- ACVB protocol [MeSH Supplementary Concept]
- AD 202 [MeSH Supplementary Concept]
- AD 70 [MeSH Supplementary Concept]
- ADIC protocol [MeSH Supplementary Concept]
- ADM protocol [MeSH Supplementary Concept]
- ADOAP protocol [MeSH Supplementary Concept]
- ADOC protocol [MeSH Supplementary Concept]
- AFC regimen [MeSH Supplementary Concept]
- ALF protocol [MeSH Supplementary Concept]
- ALL-80 protocol [MeSH Supplementary Concept]
- ALL-82 protocol [MeSH Supplementary Concept]
- AMF protocol [MeSH Supplementary Concept]
- AN 204 [MeSH Supplementary Concept]
- AN 207 [MeSH Supplementary Concept]
- AN 215 [MeSH Supplementary Concept]
- AN 238 [MeSH Supplementary Concept]
- ANAVACYM protocol [MeSH Supplementary Concept]
- ANG 1007 [MeSH Supplementary Concept]
- AOPE protocol [MeSH Supplementary Concept]
- AP protocol 1 [MeSH Supplementary Concept]
- APEL protocol [MeSH Supplementary Concept]
- APO combination [MeSH Supplementary Concept]
- APO protocol 2 [MeSH Supplementary Concept]
- AS ODN-DOX conjugate [MeSH Supplementary Concept]
- ASHAP protocol [MeSH Supplementary Concept]
- AT protocol [MeSH Supplementary Concept]
- AVBP protocol [MeSH Supplementary Concept]
- AVCF protocol [MeSH Supplementary Concept]
- AVCT protocol [MeSH Supplementary Concept]
- AVI protocol [MeSH Supplementary Concept]
- AVIP protocol [MeSH Supplementary Concept]
- AVLF protocol [MeSH Supplementary Concept]
- AVM protocol [MeSH Supplementary Concept]
- AVPP protocol [MeSH Supplementary Concept]
- AVTMF protocol [MeSH Supplementary Concept]
- AVV protocol [MeSH Supplementary Concept]
- B-8801 protocol [MeSH Supplementary Concept]
- B-CAVe protocol [MeSH Supplementary Concept]
- B-DOPA protocol [MeSH Supplementary Concept]
- BACOD protocol [MeSH Supplementary Concept]
- BACOD-VP16 protocol [MeSH Supplementary Concept]
- BACON protocol [MeSH Supplementary Concept]
- BAFMi protocol [MeSH Supplementary Concept]
- BAP regimen [MeSH Supplementary Concept]
- BAPP protocol [MeSH Supplementary Concept]
- BEACOPP protocol [MeSH Supplementary Concept]
- BECALM protocol [MeSH Supplementary Concept]
- BEMOP-CA protocol [MeSH Supplementary Concept]
- BFM 78 protocol [MeSH Supplementary Concept]
- BFM-ALL 81 protocol [MeSH Supplementary Concept]
- BOAP protocol [MeSH Supplementary Concept]
- BOP-CISCA-POMB-ACE regimen [MeSH Supplementary Concept]
- BOVAPEC protocol [MeSH Supplementary Concept]
- BR96-doxorubicin immunoconjugate [MeSH Supplementary Concept]
- BV-CAP protocol [MeSH Supplementary Concept]
- Berlin-Frankfurt-Muenster protocol II [MeSH Supplementary Concept]
- C-13 deoxydoxorubicin [MeSH Supplementary Concept]
- C-VAMP protocol [MeSH Supplementary Concept]
- CAB protocol [MeSH Supplementary Concept]
- CAD protocol 2 [MeSH Supplementary Concept]
- CAD protocol 3 [MeSH Supplementary Concept]
- CADOM protocol [MeSH Supplementary Concept]
- CAE-P protocol [MeSH Supplementary Concept]
- CAEVM protocol [MeSH Supplementary Concept]
- CAF protocol [MeSH Supplementary Concept]
- CAF protocol 2 [MeSH Supplementary Concept]
- CAF-PH protocol [MeSH Supplementary Concept]
- CAFVP protocol [MeSH Supplementary Concept]
- CALF protocol [MeSH Supplementary Concept]
- CAM combination [MeSH Supplementary Concept]
- CAMBO-VIP protocol [MeSH Supplementary Concept]
- CAMEO protocol [MeSH Supplementary Concept]
- CAMF protocol [MeSH Supplementary Concept]
- CAMFTP protocol [MeSH Supplementary Concept]
- CAMP protocol [MeSH Supplementary Concept]
- CAMP-L protocol [MeSH Supplementary Concept]
- CAP protocol 1 [MeSH Supplementary Concept]
- CAP protocol 2 [MeSH Supplementary Concept]
- CAP-1 protocol [MeSH Supplementary Concept]
- CAP-M protocol [MeSH Supplementary Concept]
- CAPABLE protocol [MeSH Supplementary Concept]
- CAPE protocol [MeSH Supplementary Concept]
- CAPE-PALE protocol [MeSH Supplementary Concept]
- CAPF protocol [MeSH Supplementary Concept]
- CAPT protocol [MeSH Supplementary Concept]
- CARA protocol [MeSH Supplementary Concept]
- CAV protocol [MeSH Supplementary Concept]
- CAV-HEM protocol [MeSH Supplementary Concept]
- CAV-T protocol [MeSH Supplementary Concept]
- CAVB protocol [MeSH Supplementary Concept]
- CCAVP16 protocol [MeSH Supplementary Concept]
- CCV-AV protocol [MeSH Supplementary Concept]
- CE-CAP protocol [MeSH Supplementary Concept]
- CEA protocol [MeSH Supplementary Concept]
- CEBA combination [MeSH Supplementary Concept]
- CECA protocol [MeSH Supplementary Concept]
- CEVAD protocol [MeSH Supplementary Concept]
- CHAC-1 protocol [MeSH Supplementary Concept]
- CHAMOCA regimen [MeSH Supplementary Concept]
- CHAMOMA protocol [MeSH Supplementary Concept]
- CHAMP-5 protocol [MeSH Supplementary Concept]
- CHEP protocol [MeSH Supplementary Concept]
- CHOEP protocol [MeSH Supplementary Concept]
- CHOP protocol [MeSH Supplementary Concept]
- CHOP protocol, modified [MeSH Supplementary Concept]
- CHOP-B protocol [MeSH Supplementary Concept]
- CHOP-V-MMV protocol [MeSH Supplementary Concept]
- CHOP-VP16 protocol [MeSH Supplementary Concept]
- CHVP protocol [MeSH Supplementary Concept]
- CHVP regimen [MeSH Supplementary Concept]
- CHVmP-VB protocol [MeSH Supplementary Concept]
- CISCA protocol [MeSH Supplementary Concept]
- CISCA(II)-VB(IV) protocol [MeSH Supplementary Concept]
- CMFDV protocol [MeSH Supplementary Concept]
- CNR-NEO 2 protocol [MeSH Supplementary Concept]
- COATA protocol [MeSH Supplementary Concept]
- CODBLAM IV protocol [MeSH Supplementary Concept]
- COMP-VAN protocol [MeSH Supplementary Concept]
- COMPA protocol [MeSH Supplementary Concept]
- COMPA regimen [MeSH Supplementary Concept]
- COP-BLAM protocol [MeSH Supplementary Concept]
- COPAC protocol [MeSH Supplementary Concept]
- COPAD protocol [MeSH Supplementary Concept]
- COPADEM protocol [MeSH Supplementary Concept]
- COPP-ABVD protocol [MeSH Supplementary Concept]
- COSS-86 protocol [MeSH Supplementary Concept]
- CPDD protocol [MeSH Supplementary Concept]
- CTR III protocol [MeSH Supplementary Concept]
- CTVP protocol [MeSH Supplementary Concept]
- CVACE protocol [MeSH Supplementary Concept]
- CVAD protocol [MeSH Supplementary Concept]
- CVAD-V protocol [MeSH Supplementary Concept]
- CVPPABO protocol [MeSH Supplementary Concept]
- CYOMAD protocol [MeSH Supplementary Concept]
- CYVADIC protocol [MeSH Supplementary Concept]
- CephDox [MeSH Supplementary Concept]
- Cis-VACD protocol [MeSH Supplementary Concept]
- CyADIC regimen [MeSH Supplementary Concept]
- D(A)AT protocol [MeSH Supplementary Concept]
- DAC protocol [MeSH Supplementary Concept]
- DAC protocol 2 [MeSH Supplementary Concept]
- DAT protocol 2 [MeSH Supplementary Concept]
- DAVH protocol [MeSH Supplementary Concept]
- DAVTH protocol [MeSH Supplementary Concept]
- DAVTHML regimen [MeSH Supplementary Concept]
- DCCM protocol [MeSH Supplementary Concept]
- DECAV protocol [MeSH Supplementary Concept]
- DFCI 91-01 protocol [MeSH Supplementary Concept]
- DFCI 95-01 protocol [MeSH Supplementary Concept]
- DGM-1 conjugate [MeSH Supplementary Concept]
- DGM-2 conjugate [MeSH Supplementary Concept]
- DMAP protocol [MeSH Supplementary Concept]
- DOXO-EMCH [MeSH Supplementary Concept]
- DT PACE regimen [MeSH Supplementary Concept]
- DT-PACE protocol [MeSH Supplementary Concept]
- DTS-201 [MeSH Supplementary Concept]
- DVP regimen [MeSH Supplementary Concept]
- DVPP protocol [MeSH Supplementary Concept]
- DoVA protocol [MeSH Supplementary Concept]
- Dox-SynB1 conjugate [MeSH Supplementary Concept]
- EAC regimen [MeSH Supplementary Concept]
- EACB protocol [MeSH Supplementary Concept]
- EAP protocol [MeSH Supplementary Concept]
- EBAP protocol [MeSH Supplementary Concept]
- ECAPP protocol [MeSH Supplementary Concept]
- ECHO protocol [MeSH Supplementary Concept]
- EMACO protocol [MeSH Supplementary Concept]
- ENSG 3C protocol [MeSH Supplementary Concept]
- EPOCH protocol [MeSH Supplementary Concept]
- EVA regimen [MeSH Supplementary Concept]
- EVAC protocol [MeSH Supplementary Concept]
- EVAC-G-CSF protocol [MeSH Supplementary Concept]
- EVAP protocol [MeSH Supplementary Concept]
- F-MACHOP protocol [MeSH Supplementary Concept]
- FAB protocol [MeSH Supplementary Concept]
- FAC-MV protocol [MeSH Supplementary Concept]
- FACP protocol [MeSH Supplementary Concept]
- FADIP protocol [MeSH Supplementary Concept]
- FAM II protocol [MeSH Supplementary Concept]
- FAM protocol [MeSH Supplementary Concept]
- FAM-S protocol [MeSH Supplementary Concept]
- FAMMe protocol [MeSH Supplementary Concept]
- FAMP protocol [MeSH Supplementary Concept]
- FAMe protocol [MeSH Supplementary Concept]
- FAN regimen [MeSH Supplementary Concept]
- FAP protocol [MeSH Supplementary Concept]
- FAP regimen [MeSH Supplementary Concept]
- FAP2 protocol [MeSH Supplementary Concept]
- FAPEL protocol [MeSH Supplementary Concept]
- FEPA protocol [MeSH Supplementary Concept]
- FLAP protocol [MeSH Supplementary Concept]
- FLAP regimen [MeSH Supplementary Concept]
- FOAM protocol [MeSH Supplementary Concept]
- FTM protocol [MeSH Supplementary Concept]
- FTP protocol [MeSH Supplementary Concept]
- FUDRAM protocol [MeSH Supplementary Concept]
- FUVA protocol [MeSH Supplementary Concept]
- GIMEMA LAL 0288 protocol [MeSH Supplementary Concept]
- HAC protocol [MeSH Supplementary Concept]
- HATP protocol [MeSH Supplementary Concept]
- HCOMLA protocol [MeSH Supplementary Concept]
- HCVAD protocol [MeSH Supplementary Concept]
- HEAVD protocol [MeSH Supplementary Concept]
- HELP protocol [MeSH Supplementary Concept]
- HFAP protocol [MeSH Supplementary Concept]
- HM 89 protocol [MeSH Supplementary Concept]
- HM 91 protocol [MeSH Supplementary Concept]
- HOAAP protocol [MeSH Supplementary Concept]
- HOAP-Bleo protocol [MeSH Supplementary Concept]
- HOPE-Bleo protocol [MeSH Supplementary Concept]
- HPMA coploymer-doxorubicin-galactosamine [MeSH Supplementary Concept]
- HPMA copolymer-Dox-AGM [MeSH Supplementary Concept]
- IAP protocol [MeSH Supplementary Concept]
- IMAP protocol [MeSH Supplementary Concept]
- IMMU-110 [MeSH Supplementary Concept]
- IVAD protocol [MeSH Supplementary Concept]
- IVADIC regimen [MeSH Supplementary Concept]
- JAC protocol [MeSH Supplementary Concept]
- K1 protocol [MeSH Supplementary Concept]
- L 377202 [MeSH Supplementary Concept]
- LEAMP protocol [MeSH Supplementary Concept]
- LEG-3 prodrug [MeSH Supplementary Concept]
- LHRH, lysine(6)-doxorubicin [MeSH Supplementary Concept]
- LMB89 protocol [MeSH Supplementary Concept]
- LNH 84 protocol [MeSH Supplementary Concept]
- LNH 87 protocol [MeSH Supplementary Concept]
- LNH-80 regimen [MeSH Supplementary Concept]
- LSA(2)L(2) protocol [MeSH Supplementary Concept]
- LSG15 regimen [MeSH Supplementary Concept]
- M-BACOD protocol [MeSH Supplementary Concept]
- M-BACOP protocol [MeSH Supplementary Concept]
- M-BACOS protocol [MeSH Supplementary Concept]
- M-VAC protocol [MeSH Supplementary Concept]
- MAB protocol [MeSH Supplementary Concept]
- MABOP protocol [MeSH Supplementary Concept]
- MAC-VD protocol [MeSH Supplementary Concept]
- MACC combination [MeSH Supplementary Concept]
- MACOP-B protocol [MeSH Supplementary Concept]
- MACOP-B regimen [MeSH Supplementary Concept]
- MADDOC protocol [MeSH Supplementary Concept]
- MAID protocol [MeSH Supplementary Concept]
- MALF protocol [MeSH Supplementary Concept]
- MAP protocol [MeSH Supplementary Concept]
- MAPECO protocol [MeSH Supplementary Concept]
- MATCOP regimen [MeSH Supplementary Concept]
- MCC465 [MeSH Supplementary Concept]
- MCHOD protocol [MeSH Supplementary Concept]
- ME 2303 [MeSH Supplementary Concept]
- MECHOP-BM protocol [MeSH Supplementary Concept]
- MEN 11609 [MeSH Supplementary Concept]
- MEVAP protocol [MeSH Supplementary Concept]
- MFAV protocol [MeSH Supplementary Concept]
- ML-Y1 protocol [MeSH Supplementary Concept]
- MOP-BAP protocol [MeSH Supplementary Concept]
- MOPP-ABV protocol [MeSH Supplementary Concept]
- MOPPEBVCAD protocol [MeSH Supplementary Concept]
- MTX-CHOP protocol [MeSH Supplementary Concept]
- MVP-CAB protocol [MeSH Supplementary Concept]
- Murphy-Bowmann protocol [MeSH Supplementary Concept]
- N,N-bis(3-pyridylmethyl)adriamycin [MeSH Supplementary Concept]
- N,N-dimethyladriamycin-14-valerate [MeSH Supplementary Concept]
- N,N-dimethyldoxorubicin [MeSH Supplementary Concept]
- N-(2-hydroxyethyl)doxorubicin [MeSH Supplementary Concept]
- N-(2-hydroxypropyl)methacrylamide co-polymer-doxorubicin conjugate [MeSH Supplementary Concept]
- N-(3-pyridylmethyl)adriamycin [MeSH Supplementary Concept]
- N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate [MeSH Supplementary Concept]
- N-(4-glucuronyl-3-nitrobenzyloxycarbonyl)doxorubicin [MeSH Supplementary Concept]
- N-(5,5-diacetoxypentyl)doxorubicin [MeSH Supplementary Concept]
- N-(5-(4-(3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)but-2-ynyloxymethyl)-2-methoxybenzamidomethyl)doxorubicin [MeSH Supplementary Concept]
- N-(succinyl-beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin [MeSH Supplementary Concept]
- N-acetyldoxorubicn [MeSH Supplementary Concept]
- N-alanyl-leucyl-alanyl-leucyl-doxorubicin [MeSH Supplementary Concept]
- N-benzyladriamycin [MeSH Supplementary Concept]
- N-benzyladriamycin-14-valerate [MeSH Supplementary Concept]
- N-benzyloxycarbonyl-alanyl-alanyl-aspartyl-doxorubicin [MeSH Supplementary Concept]
- N-leucyldoxorubicin [MeSH Supplementary Concept]
- N-trifluoroacetyladriamycin [MeSH Supplementary Concept]
- N-trifluoroacetyladriamycin-14-O-hemiadipate [MeSH Supplementary Concept]
- N-trifluoroacetyladriamycinol [MeSH Supplementary Concept]
- N4SE protocol [MeSH Supplementary Concept]
- NEO-MACOP-B protocol [MeSH Supplementary Concept]
- NIACF regimen [MeSH Supplementary Concept]
- NK911 [MeSH Supplementary Concept]
- NSC 354646 [MeSH Supplementary Concept]
- OOS-A regimen [MeSH Supplementary Concept]
- OPAL protocol [MeSH Supplementary Concept]
- OPEC-D protocol [MeSH Supplementary Concept]
- OS 87 protocol [MeSH Supplementary Concept]
- P-DOCE protocol [MeSH Supplementary Concept]
- PAB-CAP protocol [MeSH Supplementary Concept]
- PABlOE protocol [MeSH Supplementary Concept]
- PACE-BOM protocol [MeSH Supplementary Concept]
- PACEBO protocol [MeSH Supplementary Concept]
- PADIC protocol [MeSH Supplementary Concept]
- PAFT protocol [MeSH Supplementary Concept]
- PAIV protocol [MeSH Supplementary Concept]
- PAV-M protocol [MeSH Supplementary Concept]
- PAVE protocol 2 [MeSH Supplementary Concept]
- PAVI protocol [MeSH Supplementary Concept]
- PCAV protocol [MeSH Supplementary Concept]
- PEG-PAsp(Dox) [MeSH Supplementary Concept]
- PFAP protocol [MeSH Supplementary Concept]
- PIAF regimen [MeSH Supplementary Concept]
- PM-FAC protocol [MeSH Supplementary Concept]
- POCAL protocol [MeSH Supplementary Concept]
- POMACE protocol [MeSH Supplementary Concept]
- POMB-ACE-PAV regimen [MeSH Supplementary Concept]
- PPA protocol [MeSH Supplementary Concept]
- PROMACE protocol [MeSH Supplementary Concept]
- PROMACE-CytaBOM protocol [MeSH Supplementary Concept]
- PTP protocol [MeSH Supplementary Concept]
- PVA protocol [MeSH Supplementary Concept]
- PVP protocol 3 [MeSH Supplementary Concept]
- PhAc-ALGP-doxorubicin [MeSH Supplementary Concept]
- Pro-MACE-C-MOPP protocol [MeSH Supplementary Concept]
- ProMACE-MOPP protocol [MeSH Supplementary Concept]
- R-14 regimen [MeSH Supplementary Concept]
- R-CHOP protocol [MeSH Supplementary Concept]
- RGDm-SSL-DOX [MeSH Supplementary Concept]
- SCAB protocol [MeSH Supplementary Concept]
- SP 1049C [MeSH Supplementary Concept]
- SSG IX protocol [MeSH Supplementary Concept]
- ST 9802 [MeSH Supplementary Concept]
- ST 9905 [MeSH Supplementary Concept]
- SUPERFAN regimen [MeSH Supplementary Concept]
- SW43-DOX compound [MeSH Supplementary Concept]
- Stanford-NCOG protocol [MeSH Supplementary Concept]
- T-6 protocol [MeSH Supplementary Concept]
- T10 A protocol [MeSH Supplementary Concept]
- T10-ERK-DOX compound [MeSH Supplementary Concept]
- T7 protocol [MeSH Supplementary Concept]
- TAC protocol [MeSH Supplementary Concept]
- TAP protocol [MeSH Supplementary Concept]
- TAPA protocol [MeSH Supplementary Concept]
- TAVH protocol [MeSH Supplementary Concept]
- TCAP protocol [MeSH Supplementary Concept]
- TCCSG B-8801 protocol [MeSH Supplementary Concept]
- THP-COPBLM regimen [MeSH Supplementary Concept]
- THP-FLPM protocol [MeSH Supplementary Concept]
- TNCF regimen [MeSH Supplementary Concept]
- V-CAM protocol [MeSH Supplementary Concept]
- VAA protocol [MeSH Supplementary Concept]
- VAAP regimen [MeSH Supplementary Concept]
- VAB-IV protocol [MeSH Supplementary Concept]
- VABCD protocol [MeSH Supplementary Concept]
- VABE protocol [MeSH Supplementary Concept]
- VAC-M protocol [MeSH Supplementary Concept]
- VAC-MAP protocol [MeSH Supplementary Concept]
- VACA protocol [MeSH Supplementary Concept]
- VACAD protocol [MeSH Supplementary Concept]
- VACIME protocol [MeSH Supplementary Concept]
- VACO-B protocol [MeSH Supplementary Concept]
- VACOP-B protocol [MeSH Supplementary Concept]
- VAD I protocol [MeSH Supplementary Concept]
- VAD combination [MeSH Supplementary Concept]
- VAD protocol [MeSH Supplementary Concept]
- VAD regimen 2 [MeSH Supplementary Concept]
- VAD1 regimen [MeSH Supplementary Concept]
- VADIC protocol [MeSH Supplementary Concept]
- VAIA protocol [MeSH Supplementary Concept]
- VAIP protocol [MeSH Supplementary Concept]
- VAM protocol [MeSH Supplementary Concept]
- VAMP protocol [MeSH Supplementary Concept]
- VAMP regimen [MeSH Supplementary Concept]
- VAMP-EEE protocol [MeSH Supplementary Concept]
- VAMP-ME protocol [MeSH Supplementary Concept]
- VAP combination [MeSH Supplementary Concept]
- VAP protocol [MeSH Supplementary Concept]
- VAP regimen [MeSH Supplementary Concept]
- VAP-cyclo protocol [MeSH Supplementary Concept]
- VAPA protocol [MeSH Supplementary Concept]
- VAPAC protocol [MeSH Supplementary Concept]
- VAPE protocol [MeSH Supplementary Concept]
- VAPEC-B protocol [MeSH Supplementary Concept]
- VATA protocol [MeSH Supplementary Concept]
- VAU regimen [MeSH Supplementary Concept]
- VAV protocol [MeSH Supplementary Concept]
- VBA protocol [MeSH Supplementary Concept]
- VBAD protocol [MeSH Supplementary Concept]
- VBAMDex protocol [MeSH Supplementary Concept]
- VBAP protocol [MeSH Supplementary Concept]
- VCAA protocol [MeSH Supplementary Concept]
- VCAD regimen [MeSH Supplementary Concept]
- VCAV protocol [MeSH Supplementary Concept]
- VCDP protocol [MeSH Supplementary Concept]
- VCMA protocol [MeSH Supplementary Concept]
- VDBCP protocol [MeSH Supplementary Concept]
- VECABOP protocol [MeSH Supplementary Concept]
- VEMFAH protocol [MeSH Supplementary Concept]
- VEP-THP protocol [MeSH Supplementary Concept]
- VEPA-B protocol [MeSH Supplementary Concept]
- VEPA-L protocol [MeSH Supplementary Concept]
- VEPA-M protocol [MeSH Supplementary Concept]
- VIA protocol [MeSH Supplementary Concept]
- VPA protocol [MeSH Supplementary Concept]
- VPCBAE protocol [MeSH Supplementary Concept]
- VPD protocol [MeSH Supplementary Concept]
- VPDA protocol [MeSH Supplementary Concept]
- VTMFAP protocol [MeSH Supplementary Concept]
- WP 936 [MeSH Supplementary Concept]
- acetyl-phenylalanyl-lysyl-para-aminobenzyloxycarbonyl-adriamycin [MeSH Supplementary Concept]
- aconityldoxorubicin [MeSH Supplementary Concept]
- adriamycin octanoylhydrazone [MeSH Supplementary Concept]
- adriamycin semiquinone radicals [MeSH Supplementary Concept]
- adriamycin-14-valerate [MeSH Supplementary Concept]
- adriamycin-cardiolipin complex [MeSH Supplementary Concept]
- adriamycin-glutathione adduct [MeSH Supplementary Concept]
- adriamycinol [MeSH Supplementary Concept]
- annamycin [MeSH Supplementary Concept]
- apoferritin doxorubicin [MeSH Supplementary Concept]
- bio-adhesio-chemo protocol [MeSH Supplementary Concept]
- carboxymethylpullulan-phenylglycyl-doxorubicin conjugate [MeSH Supplementary Concept]
- cis-(platinum-dichloro(doxorubicin)(tert-butylamine)) [MeSH Supplementary Concept]
- desacetyladriamycin [MeSH Supplementary Concept]
- dox-penetratin conjugate [MeSH Supplementary Concept]
- doxazolidine [MeSH Supplementary Concept]
- doxoform [MeSH Supplementary Concept]
- doxorubicin 4-(maleimid-1-yl)phenylacetylhydrazone [MeSH Supplementary Concept]
- doxorubicin cysteinyl-asparagyl-glycyl-arginyl-cysteine conjugate [MeSH Supplementary Concept]
- doxorubicin polyaspartic acid conjugate [MeSH Supplementary Concept]
- doxorubicin(6-maleimidocaproyl)hydrazone [MeSH Supplementary Concept]
- doxorubicin-14-O-hemiadipate [MeSH Supplementary Concept]
- doxorubicin-1G3.10-monoclonal antibody conjugate [MeSH Supplementary Concept]
- doxorubicin-BSA conjugate [MeSH Supplementary Concept]
- doxorubicin-DNA [MeSH Supplementary Concept]
- doxorubicin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate [MeSH Supplementary Concept]
- doxorubicin-N-(2-hydroxypropyl)methacrylamide galactosamine conjugate [MeSH Supplementary Concept]
- doxorubicin-N-4-hydroxyphenoxyacetamide [MeSH Supplementary Concept]
- doxorubicin-aluminum complex [MeSH Supplementary Concept]
- doxorubicin-cobalt(II) complex [MeSH Supplementary Concept]
- doxorubicin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer [MeSH Supplementary Concept]
- doxorubicin-conjugated poly-(L-lactic acid)-di-block-methoxypoly(ethylene glycol) [MeSH Supplementary Concept]
- doxorubicin-copper(II) complex [MeSH Supplementary Concept]
- doxorubicin-ferric-ADP complex [MeSH Supplementary Concept]
- doxorubicin-gallium-transferrin conjugate [MeSH Supplementary Concept]
- doxorubicin-heparin [MeSH Supplementary Concept]
- doxorubicin-iron complex [MeSH Supplementary Concept]
- doxorubicin-pyran copolymer conjugate [MeSH Supplementary Concept]
- doxorubicin-transferrin conjugate [MeSH Supplementary Concept]
- doxorubucin cysteinyl-aspartyl-cysteinyl-arginyl-glycyl-aspartyl-cycsteinyl-phenylalanyl-cysteine conjugate [MeSH Supplementary Concept]
- esorubicin [MeSH Supplementary Concept]
- gancotamab [MeSH Supplementary Concept]
- gelatin-doxorubicin [MeSH Supplementary Concept]
- glutaryl-hydroxyprolyl-alanyl-seryl-cyclohexylglycyl-glutaminyl-seryl-leucyl-doxorubicin [MeSH Supplementary Concept]
- glutathione pegylated liposomal doxorubicin [MeSH Supplementary Concept]
- glutathione-doxorubicin conjugate [MeSH Supplementary Concept]
- glycothiohexide alpha aglycone [MeSH Supplementary Concept]
- indium DTPA-adriamycin [MeSH Supplementary Concept]
- kigamicin A [MeSH Supplementary Concept]
- kigamicin B [MeSH Supplementary Concept]
- kigamicin C [MeSH Supplementary Concept]
- kigamicin D [MeSH Supplementary Concept]
- kigamicin E [MeSH Supplementary Concept]
- liposomal doxorubicin [MeSH Supplementary Concept]
- m-ACOD protocol [MeSH Supplementary Concept]
- m-M-BACOD protocol [MeSH Supplementary Concept]
- maleimidoethyliminodiacetylbis(Phe-Lys-PABC-DOX) mTEG hydrazone [MeSH Supplementary Concept]
- maleimidoethyliminodiacetylbis(Val-Lys-PABC-DOX) mTEG hydrazone [MeSH Supplementary Concept]
- maleimidohexyl-arginyl-arginyl-alanyl-leucyl-alanyl-leucyl-doxorubicin [MeSH Supplementary Concept]
- methoxy-morpholinyl-doxorubicin [MeSH Supplementary Concept]
- modified M-VAC protocol [MeSH Supplementary Concept]
- morpholinocarbonyl-His-Ser-Ser-Lys-Leu-Gln-Leu-doxorubicin [MeSH Supplementary Concept]
- nemorubicin [MeSH Supplementary Concept]
- nocathiacin III [MeSH Supplementary Concept]
- pentyl 4-(N-doxazolidinylcarbonyloxymethyl)phenylcarbamate [MeSH Supplementary Concept]
- pirarubicin [MeSH Supplementary Concept]
- quelamycin [MeSH Supplementary Concept]
- ristocetin aglycon [MeSH Supplementary Concept]
- rizzoli IOR protocol [MeSH Supplementary Concept]
- rosen's T-10 protocol [MeSH Supplementary Concept]
- sabarubicin [MeSH Supplementary Concept]
- st jude's regimen [MeSH Supplementary Concept]
- stanford V protocol [MeSH Supplementary Concept]
- stanford university protocol [MeSH Supplementary Concept]
- technetium 99m folate-polyethylene glycol-doxorubicin [MeSH Supplementary Concept]
- trifluoroacetyladriamycin-14-octanoate [MeSH Supplementary Concept]
- valrubicin [MeSH Supplementary Concept]
- wED protocol [MeSH Supplementary Concept]
Semantic type(s)
- Antibiotic [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
UMLS correspondences (same concept)
- DOXOrubicin [LOINC component]
- Doxorubicin [ICD-11 Extension code]
- Doxorubicin [NCIt concept]
- Doxorubicin (substance) [SNOMED CT concept]
- Product containing doxorubicin (medicinal product) [SNOMED CT concept]
- doxorubicin [ATC Code]
- doxorubicin [Substance BNPC]
- doxorubicin [SNOMED Notion]
Validated automatic mappings to BTNT
- Doxorubicin Hydrochloride [NCIt concept]
- Doxorubicin hydrochloride [SMS substance]
- Doxorubicin hydrochloride (substance) [SNOMED CT concept]
- Doxorubicin liposome (substance) [SNOMED CT concept]
- Pegylated Liposomal Doxorubicin Hydrochloride [NCIt concept]
- doxorubicin [ATC Code]
- doxorubicin hydrochloride [Substance BNPC]
- doxorubicin hydrochloride [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients